Evaluation of cost-utility of varenicline compared with existing smoking cessation therapies in South Korea

Value in Health

Volumn 12, Issue SUPPL. 3, 2009, Pages

  Bae, Jung Youn ^a   Kim, Cheol Hwan ^b   Lee, Eui Kyung ^a  

^a Sookmyung Women's University   (South Korea)

^b Inje University College of Medicine   (South Korea)

Author keywords

Cost utility analysis; Markov model; Pharmocoeconomics; Smoking cessation

Indexed keywords

AMFEBUTAMONE; NICOTINE; VARENICLINE;

ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG EFFICACY; HUMAN; MONEY; NICOTINE REPLACEMENT THERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; SMOKING; SMOKING CESSATION; SOUTH KOREA;

EID: 72149086927     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2009.00631.x     Document Type: Article

References (16)

1. Health Insurance Review and Assessment Service. Pharmacoeconomic Guidelines and Points to Prepare Submissions. Seoul, South Korea : Health Insurance Review And Assessment Service, 2006.
2. Howard P, Knight C, Boler A, et al. Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO simulation model: application to a population of US adult smokers. Pharmacoeconomics 2008 26 : 497 511.
3. Bolin K, Mörk AC, Willers S, et al. Varenicline as compared to bupropion in smoking-cessation therapy - cost-utility results for Sweden 2003. Respir Med 2008 102 : 699 710.
4. Hoogendoorn M, Welsing P, Rutten-van Mölken MP. Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands. Curr Med Res Opin 2008 24 : 51 61.
5. Lee HY, Yoon SJ, Ahn HS. Measuring the burden of major cancers due to smoking in Korea. Cancer Sci 2006 97 : 530 534.
6. Korea Institute for Health and Social Affairs. The Third National Health and Nutrition Examination Survey. Seoul, South Korea : Korea Institute for Health and Social Affairs, 2005.
7. Jee SH, Jo IH, Yun JE, et al. Smoking and cause of death in Korea: 11 years follow-up prospective study. Korean J Epidemiol 2005 27 : 182 190.
8. Korea National Statistical Office. National Statistical Office (2005) Annual report on the cause of death statistics. Available from: http://www.kosis.kr [Accessed September 1, 2007 S, Sakakibara H, Motani S, et al. Incidence of chronic obstructive pulmonary disease, and the relationship between age and smoking in a Japanese population. J Epidemiol 2007 17 : 54 60.
9. Ministry for Health, Welfare and Family Affairs. 1999-2001 Cancer Incidence in Korea (2005). Seoul, South Korea : Ministry for Health, Welfare and Family Affairs, 2005.
10. US Department of Health and Human Services. The Health Consequences of Smoking: A Report of the Surgeon General. Atlanta, GA : US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2004.
11. Thun MJ. Smoking vs. other risk factors as the cause of smoking attributable deaths: confounding in the courtroom. JAMA 2000 284 : 706 712.
12. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006 296 : 47 55.
13. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006 296 : 56 63.
14. Nides M, Oncken C, Gonzales D, et al. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med 2006 166 : 1561 1568.
15. Oncken C, Gonzales D, Nides M, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med 2006 166 : 1571 1577.
16. Nakamura M, Oshima A, Fujimoto Y, et al. Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. Clin Ther 2007 29 : 1040 1056.